Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD and Safety of CKD-381 vs Nexium in Healthy Subjects
NCT03211143Phase 1Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Jun 2017
- Primary completion
- Aug 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of esomeprazole + sodium bicarbonate in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Area under the plasma drug concentration-time curve within a dosing interval and Percent decrease from baseline in integrated gastric acidity. Started Jun 2017; status: completed.
02
Drugs
esomeprazole + sodium bicarbonate
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03211143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03211143.